Journal ArticleDOI
Colestipol hydrochloride, a new hypolipidemic drug: a two-year study.
Cooper Ee,Michel Am +1 more
TLDR
Colestipol hydrochloride is an insoluble, nonabsorbable copolymer with bile-acid-binding capacity that prevents reabsorption of cholates from the intestinal tract into the enterohepatic circulation causing a net loss of bile acids, and therefore of cholesterol.Abstract:
Colestipol hydrochloride is an insoluble, nonabsorbable copolymer with bile-acid-binding capacity. It prevents reabsorption of cholates from the intestinal tract into the enterohepatic circulation causing a net loss of bile acids, and therefore of cholesterol. Sixty subjects with cholesterol levels over 250 mg/100 ml were studied for 104 weeks. Patients with normal phenotypes, types 2,3, and 4, were given 5 gm three times daily and experienced an average drop of 40 mg/100 ml (14%). While patients with types 2,3, and 4 hyperlipidemia responded effectively, cholesterol levels in type 2 patients dropped earliest and most consistently with an average decrease of 58 mg/100 ml (19%). A comparable group of patients with hyperlipidemia taking placebo showed on average no change in serum cholesterol. Serum triglyceride values were not altered significantly. The resin is not absorbed from the gastrointestinal tract and produces a slight increase in fecal volume. Results of chemistries, enzyme assays, prothrombin times, hematology, and urinalysis and body weights wer unaltered. There was no evidence of lithogenic bile production. Colestipol is a tasteless and ordorless copolymer with high acceptability. Side effects were limited to occasional bloating, gas, and constipation. The drug is a safe, effective, palatable hypolipedmic agent.read more
Citations
More filters
Journal ArticleDOI
Discontinuation of antihyperlipidemic drugs : do rates reported in clinical trials reflect rates in primary care settings ?
Susan E. Andrade,Alexander M. Walker,Lawrence K. Gottlieb,Norman K. Hollenberg,Marcia A. Testa,Gordon M. Saperia,Richard Platt +6 more
TL;DR: The effectiveness and tolerability of antihyperlipidemic medications should be studied further in populations that typically use the agents, and in open-label studies were similar to those in the HMOs.
Journal ArticleDOI
Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.
Michael H. Davidson,Maureen A. Dillon,Bruce R. Gordon,Peter B. Jones,Julie Samuels,Stuart R. Weiss,Jonathon Isaacsohn,Phillip Toth,Steven K. Burke +8 more
TL;DR: Colesevelam therapy is effective for lowering low-density lipoprotein cholesterol concentrations in persons with moderate hypercholesterolemia and lacks the constipating effect of other bile acid sequestrants, demonstrating the potential for increased compliance.
Journal ArticleDOI
Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia.
TL;DR: Long-term colestipol and diet treatment reduced the xanthoma size and stabilized serially angiographically visualized atherosclerotic lesions in 21 of the 25 patients who showed a satisfactory hypolipemic response and did not cause nutritional or metabolic disturbances.
Journal ArticleDOI
Modification of chitosan to improve its hypocholesterolemic capacity.
TL;DR: The bile acid binding capacity of dialkylaminoalkyl chitosan derivatives increased with the number of carbons in the alkyl groups, indicating that hydrophobic interaction is a secondary factor for the sequestration of bile acids.
Journal ArticleDOI
Colestipol: A Review of its Pharmacological Properties and Therapeutic Efficacy in Patients with Hypercholesterolaemia
TL;DR: In a large multicentre study measuring mortality over a 3-year treatment period, total mortality and mortality due to cardiovascular disease were significantly lower in colestipol-treated men than in those receiving a placebo, but several difficulties with the trial design require that these reported effects on mortality be cautiously interpreted.
Related Papers (5)
Effects of colestipol (U-26,597A), a new bile acid sequestrant, on serum lipids in experimental animals and man.
Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortality☆
Long-term cholesterol-lowering effect of colestipol resin in humans.
Ludwig Gross,Roland Figueredo +1 more